Studies link the overexpression of the proapoptotic gene Bcl‐2 with the downregulated profile of miR‐181b in multi‐drug‐resistant lung cancer cells; after validation of direct inhibition of miR‐181b on Bcl‐2, replacement therapies showed significant improvement in terms of cell sensitivity to chemotherapeutic agents (Zhu et al., 2010). This evidence concerns the gene BCL2 and lung cancer.